Five issues in healthcare were spotlighted as key developments to watch; FDA to ban all e-cig vape flavors except for menthol and tobacco; Google AI system shown to improve detection of breast cancer through mammograms.
In an article published by The Hill, 5 key issues relating to healthcare warrant extensive monitoring: drug pricing, surprise billing, the Affordable Care Act (ACA), Medicare for All, and vaping. All topics have become talking points throughout 2019, with drug prices and surprise medical bills serving as the focus of bipartisan talk but no major reforms have been initiated yet. The ACA is also a trending topic with the end of the past year seeing the law deemed unconstitutional by a federal appeals court. The FDA plans to ban all e-cigarette vaping flavors except for tobacco and menthol, according to The Wall Street Journal. The ban seeks to impede the teen vaping epidemic, with fruity vaping flavors such as bubble gum shown to attract teenagers and consequently lead to nicotine addiction. The ban will also exclude open-tank vaping devices, which allow users to mix their own nicotine liquids. The official announcement is expected to come tomorrow.A Google AI system was shown in a study to be as good as expert radiologists at detecting off mammograms which women had breast cancer and showed potential at reducing errors, according to Reuters. The study, published in the journal Nature, adds to research showing the promise of AI systems in reducing errors relating to diagnosing breast cancer, with radiologists shown to miss about 20% of breast cancers in mammograms.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More